Enzymit raises $10 million Series A for cell-free bio-production technology
Enzymit raises $10 million Series A for cell-free bio-production technology
The Israeli startup is building a cell-free production platform that aims to make bioproduction faster, simpler, cost-effective, and scalable.
Enzymit, a synthetic biology company, has announced the close of its $10 million Series A funding round, led by Grove Ventures and Khosla Ventures, with participation from previous investors First Star Ventures and Sapir Venture Partners.
Founded in 2020 by Dr. Gideon Lapidoth and COO Dror Baran, Enzymit is headquartered in Ness Ziona, Israel.
The Israeli startup is building a cell-free production platform that aims to make bioproduction faster, simpler, cost-effective, and scalable. The company leverages complex computational design and deep learning algorithms to create novel enzymes for real-world applications. These tailor-made enzymes are optimized for cell-free systems, bypassing the limitations of traditional cell-based fermentation. By eliminating the need for living cells, Enzymit’s aims to make bio-production the new manufacturing standard.
“For decades, bio-production has been limited by the search for natural enzymes that might fit industrial needs,” said Dr. Gideon Lapidoth, CEO and co-founder of Enzymit. “Our AI-powered platform changes this paradigm by designing entirely new enzymes tailored for specific production challenges. This enables us to create the molecules and materials that were previously unattainable or prohibitively costly to produce.”
Enzymit’s technology spans multiple industries targeting both biochemicals and traditional chemicals. The company has already demonstrated success in producing Hyaluronic Acid (HA), a biopolymer valued for its applications in cosmetics and medicine, as well as Human Milk Oligosaccharides (HMOs), crucial prebiotics for infant nutrition.
With the backing of its Series A funding, Enzymit is moving from lab-scale production to its first pilot facility.
“The Series A funding will enable us to establish our pilot facility and begin scaling production for global distribution,” said Dror Baran, Enzymit’s COO and co-founder “Cell-free bio-production technology offers a timely solution. We’re not only making bio-production affordable; we’re fundamentally transforming how products are made.”
